Why the study?
Uncertainty remains regarding direct-acting oral anticoagulant use in several real-world clinical scenarios not fully explored in clinical trials.
A Delphi consensus of Italian physicians highlights ongoing clinical uncertainty regarding DOAC use in complex AF patients, such as the elderly, frail, and those with hyperfiltration.
BACKGROUND: In recent years, direct-acting oral anticoagulants (DOACs) have entered clinical practice for stroke prevention in non-valvular atrial fibrillation or prevention and treatment of venous thromboembolism. However, remaining uncertainty regarding DOAC use in some clinical scenarios commonly encountered in the real world has not been fully explored in clinical trials. METHODS: We report on use of a Delphi consensus process on DOAC use in non-valvular atrial fibrillation patients. The consensus process dealt with 9 main topics: (i) DOACs vs vitamin K antagonists in atrial fibrillation (AF) patients; (ii) therapeutic options for patients with stable total time in range treated with vitamin K antagonists; (iii) therapeutic options for patients aged > 85 years; (iv) therapeutic management of hyperfiltering patients; (v) pharmacologic interactions; (vi) therapeutic options in the long-term treatment (prevention) of patients with AF and acute coronary syndrome after the triple therapy; (vii) low doses of DOACs in AF patients; (viii) ischemic stroke in patients inappropriately treated with low doses of DOACs; (ix) management of patients taking DOACs with left atrial appendage thrombosis. RESULTS: A total of 101 physicians (cardiologists, internists, geriatricians, and hematologists) from Italy expressed their level of agreement on each statement by using a 5-point Likert scale (1 = strongly disagree; 2 = disagree; 3 = somewhat agree; 4 = agree; 5 = strongly agree). Votes 1-2 were considered to be disagreement; votes 3-5 were considered to be agreement. Agreement among the respondents of ≥ 66% for each statement was considered consensus. A brief discussion of the results for each topic is also reported. CONCLUSIONS: In clinical practice, there is still uncertainty on DOAC use, especially in elderly, fragile, comorbid, and hyperfiltering patients.
No takes yet. Share an insight, caveat, or question.
Mumoli et al. (2020) studied Non-valvular atrial fibrillation (n=101). Direct-acting oral anticoagulants (DOACs) was evaluated on Consensus agreement (≥ 66%) on statements regarding DOAC use. Direct-acting oral anticoagulant (DOAC) use in atrial fibrillation remains uncertain in complex patients, based on a Delphi consensus of 101 Italian physicians using a ≥66% agreement threshold.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: